The Insider Gordon Clemons Unloaded 2450 shares of CorVel (CRVL); 1 Analysts Bullish Bio-Rad Laboratories, Inc. (BIO)

CorVel Corporation (NASDAQ:CRVL) Logo

Bio-Rad Laboratories, Inc. (NYSE:BIO) Ratings Coverage

Among 3 analysts covering Bio-Rad Laboratories (NYSE:BIO), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Bio-Rad Laboratories had 4 analyst reports since February 16, 2018 according to SRatingsIntel. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) has “Buy” rating given on Tuesday, March 20 by Wells Fargo. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) has “Hold” rating given on Friday, February 16 by C.L. King. The firm has “Neutral” rating by CL King given on Friday, February 16. On Wednesday, February 28 the stock rating was maintained by Wells Fargo with “Outperform”. See Bio-Rad Laboratories, Inc. (NYSE:BIO) latest ratings:

20/03/2018 Broker: Wells Fargo Rating: Buy New Target: $290.0 Maintain
28/02/2018 Broker: Wells Fargo Old Rating: Outperform New Rating: Outperform Old Target: $290 New Target: $280 Maintain
16/02/2018 Broker: CL King Old Rating: Buy New Rating: Neutral Downgrade
16/02/2018 Broker: C.L. King Rating: Hold Downgrade

CorVel Corporation provides medical cost containment and managed care services to address the medical costs of workersÂ’ compensation benefits, automobile insurance claims, and group health insurance benefits. The company has market cap of $1.02 billion. The firm offers network solutions, including automated medical fee auditing, preferred well-known provider management and reimbursement services, retrospective utilization review, facility claim review, professional review, pharmacy services, directed care services, medicare solutions, clearinghouse services, independent medical examinations, and inpatient medical bill review. It has a 28.88 P/E ratio. It also provides a range of patient management services comprising claims management, case management, 24/7 nurse triage, utilization management, vocational rehabilitation, life care planning, disability management, liability claims management, and auto claims management services.

Gordon Clemons; that is an insider in Corvel Corp who is the newest to unload shares in the corporation for which he is presently the Chairman of the Board. He a few days ago unloaded some 2,450 shares of the company, that are priced at about $132,924 USD, that is a price-per-share of exactly $54.3. This is not his first insider trade, in the last 30 days, he sold another 19,713 shares worth $1,022,485 USD. Dated June 29, 2018 the deal document is obtainable online here. This stocks unloading was pretty sizable one, so clearly it won’t go a secret. At present, Gordon Clemons has ownership of a total of 1.95 million shares or 10.28% of Corvel Corp’s market cap (share price times the number of shares outstanding).

The stock increased 0.84% or $0.45 during the last trading session, reaching $54. About 16,159 shares traded. CorVel Corporation (NASDAQ:CRVL) has risen 13.90% since July 1, 2017 and is uptrending. It has outperformed by 1.33% the S&P500. Some Historical CRVL News: 07/03/2018 Report: Exploring Fundamental Drivers Behind Service Corporation International, CorVel, Boyd Gaming, Leucadia National, MGIC In; 31/05/2018 – Corvel 4Q Rev $144M; 27/04/2018 – CorVel Closes Below 50-Day Moving Average: Technicals; 09/03/2018 – CorVel Closes Above 200-Day Moving Average: Technicals; 31/05/2018 – Corvel 4Q EPS 47c; 16/05/2018 – CorVel Closes Above 50-Day Moving Average: Technicals; 22/04/2018 – DJ CorVel Corporation, Inst Holders, 1Q 2018 (CRVL); 17/05/2018 – CorVel Announces Fiscal Earnings Release Webcast; 31/05/2018 – CORVEL CORP CRVL.O QUARTERLY REVENUE ROSE 7.5 PCT TO $144 MLN; 31/05/2018 – CORVEL ANNOUNCES REVENUES AND EARNINGS

Since June 4, 2018, it had 0 insider purchases, and 11 sales for $4.94 million activity. 2,250 shares were sold by CLEMONS V GORDON, worth $118,906. CORSTAR HOLDINGS INC also sold $1.60 million worth of CorVel Corporation (NASDAQ:CRVL) on Thursday, June 14. $77,577 worth of CorVel Corporation (NASDAQ:CRVL) shares were sold by Saverien Michael. Another trade for 6,000 shares valued at $309,272 was made by JESSUP R JUDD on Monday, June 4.

Another recent and important CorVel Corporation (NASDAQ:CRVL) news was published by Gurufocus.com which published an article titled: “CorVel Corp (CRVL) Files 10-K for the Fiscal Year Ended on March 31, 2018” on June 08, 2018.

Investors sentiment increased to 1.33 in Q1 2018. Its up 0.42, from 0.91 in 2017Q4. It increased, as 8 investors sold CorVel Corporation shares while 37 reduced holdings. 17 funds opened positions while 43 raised stakes. 8.06 million shares or 0.63% less from 8.11 million shares in 2017Q4 were reported. Metropolitan Life Insur Co Ny reported 0% stake. Renaissance Technologies Ltd Llc holds 1.46M shares or 0.08% of its portfolio. Jefferies Group reported 0% stake. Btim Corp has 0.1% invested in CorVel Corporation (NASDAQ:CRVL). Guggenheim Capital Limited Liability Com reported 0% stake. Zebra Cap Mngmt Ltd holds 0.22% in CorVel Corporation (NASDAQ:CRVL) or 11,880 shares. Manufacturers Life Insur Communication The reported 0% in CorVel Corporation (NASDAQ:CRVL). Great West Life Assurance Can invested in 0% or 12,586 shares. California State Teachers Retirement System invested in 14,141 shares. Bessemer Group Inc owns 0% invested in CorVel Corporation (NASDAQ:CRVL) for 11,800 shares. Price T Rowe Assocs Inc Md invested 0% in CorVel Corporation (NASDAQ:CRVL). Monroe Bancorp Mi has 0% invested in CorVel Corporation (NASDAQ:CRVL) for 244 shares. Thrivent Financial For Lutherans has invested 0% in CorVel Corporation (NASDAQ:CRVL). Jpmorgan Chase & Co holds 0% of its portfolio in CorVel Corporation (NASDAQ:CRVL) for 13,335 shares. Bnp Paribas Arbitrage holds 3,042 shares.

Investors sentiment decreased to 1.03 in Q1 2018. Its down 0.10, from 1.13 in 2017Q4. It dived, as 18 investors sold Bio-Rad Laboratories, Inc. shares while 101 reduced holdings. 42 funds opened positions while 81 raised stakes. 18.53 million shares or 0.19% less from 18.57 million shares in 2017Q4 were reported. Amp Cap Limited accumulated 0.03% or 21,460 shares. Amer Intl Grp Inc Incorporated reported 40,456 shares. Adage Cap Prtn Gp Limited Liability Company has 0.04% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 75,000 shares. Polar Capital Llp owns 238,000 shares. Sector Gamma As invested in 94,240 shares. Chicago Equity Partners stated it has 0.03% in Bio-Rad Laboratories, Inc. (NYSE:BIO). 21,671 are owned by Tygh Cap Management. Cornerstone Advisors holds 0% or 5 shares. Brinker accumulated 3,681 shares. Parametric Portfolio Associates Lc has invested 0.02% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Granahan Inv Mgmt Ma has 38,065 shares. Parkside Retail Bank & Tru invested in 27 shares or 0% of the stock. Sandler Capital Management invested 0.71% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Oregon Employees Retirement Fund accumulated 7,605 shares. Great West Life Assurance Can has invested 0.01% in Bio-Rad Laboratories, Inc. (NYSE:BIO).

Since June 13, 2018, it had 0 insider buys, and 1 sale for $106,197 activity. Crowley Michael sold $106,197 worth of stock.

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company has market cap of $8.59 billion. The firm operates through two divisions, Life Science and Clinical Diagnostics. It has a 11.33 P/E ratio. The Life Science segment develops, makes, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

The stock increased 0.10% or $0.28 during the last trading session, reaching $288.54. About 140,531 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 30.04% since July 1, 2017 and is uptrending. It has outperformed by 17.47% the S&P500. Some Historical BIO News: 09/05/2018 – NYSE HALT BIO-RAD LABS B BlOb.N ADDITIONAL INFORMATION LAST $250.85000; 22/04/2018 – DJ Bio-Rad Laboratories Inc Class B, Inst Holders, 1Q 2018 (BIO.B); 07/03/2018 NYSE HALT BIO-RAD LABS B BlOb.N ADDITIONAL INFORMATION LAST $244.70000; 08/05/2018 – BIO-RAD SEES FY REV. CHANGE EX-FX +3.5% TO +4%; 08/05/2018 – BIO-RAD 1Q EPS $21.77, EST. $1.040; 18/05/2018 – Research Report Identifies Bio-Rad Laboratories, Bright Horizons Family Solutions, Corbus Pharmaceuticals, PennyMac Financial S; 16/03/2018 – Bio-Rad Laboratories Unable to File 2017 Form 10-K by March 16 Extended Deadline; 16/03/2018 – Bio-Rad Labs Delay Prompted by Conversion to New ERP System, Business Structure for European Operations; 16/03/2018 – BIO RAD LABORATORIES – CONCLUDED THAT INTERNAL CONTROL OVER FINANCIAL REPORTING WAS NOT EFFECTIVE AS OF DEC 31, 2017; 16/03/2018 – Bio-Rad Laboratories Cites Continuing Review, Audit by KPMG

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart